The company plans to file a new drug application with the FDA within the next few months for its lead product candidate, bucindolol, for the treatment of chronic heart failure in patients with a specific genetic profile. ARCA plans to market bucindolol, for which it owns exclusive worldwide rights, in the US through its own sales force.
Richard Brewer, president and CEO of Arca, said: “As we move toward the completion of our new drug application submission for bucindolol, we feel ‘ARCA biopharma’ better reflects our biological heritage in genetic targeting and focus on commercialization of pharmaceutical products for cardiovascular patients.”